"Memantine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
AMANTADINE derivative that has some dopaminergic effects. It has been proposed as an antiparkinson agent.
| Descriptor ID |
D008559
|
| MeSH Number(s) |
D02.455.426.100.050.035.500
|
| Concept/Terms |
Memantine- Memantine
- Memantin
- 1,3-Dimethyl-5-aminoadamantane
- 1-Amino-3,5-dimethyladamantane
|
Below are MeSH descriptors whose meaning is more general than "Memantine".
Below are MeSH descriptors whose meaning is more specific than "Memantine".
This graph shows the total number of publications written about "Memantine" by people in this website by year, and whether "Memantine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2008 | 2 | 1 | 3 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2022 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Memantine" by people in Profiles.
-
Wilcox MR, Nigam A, Glasgow NG, Narangoda C, Phillips MB, Patel DS, Mesbahi-Vasey S, Turcu AL, V?zquez S, Kurnikova MG, Johnson JW. Inhibition of NMDA receptors through a membrane-to-channel path. Nat Commun. 2022 07 15; 13(1):4114.
-
Isaac E, Ney D, Serruya M, Keith S, Lippa C, Sperling MR. Tolerability of memantine monotherapy versus adding memantine as combination therapy. J Natl Med Assoc. 2022 Jun; 114(3):308-313.
-
Glasgow NG, Wilcox MR, Johnson JW. Effects of Mg2+ on recovery of NMDA receptors from inhibition by memantine and ketamine reveal properties of a second site. Neuropharmacology. 2018 07 15; 137:344-358.
-
Schneider JS, Pioli EY, Jianzhong Y, Li Q, Bezard E. Effects of memantine and galantamine on cognitive performance in aged rhesus macaques. Neurobiol Aging. 2013 Apr; 34(4):1126-32.
-
Stefanacci RG. The costs of Alzheimer's disease and the value of effective therapies. Am J Manag Care. 2011 Nov; 17 Suppl 13:S356-62.
-
Louboutin JP, Agrawal L, Reyes BA, Van Bockstaele EJ, Strayer DS. HIV-1 gp120-induced injury to the blood-brain barrier: role of metalloproteinases 2 and 9 and relationship to oxidative stress. J Neuropathol Exp Neurol. 2010 Aug; 69(8):801-16.
-
Piovesan EJ, Randunz V, Utiumi M, Lange MC, Kowacs PA, Mulinari RA, Oshinsky M, Vital M, Sereniki A, Fernandes AF, e Silva LL, Werneck LC. Influence of NMDA and non-NMDA antagonists on acute and inflammatory pain in the trigeminal territory: a placebo control study. Arq Neuropsiquiatr. 2008 Dec; 66(4):837-43.
-
Bigal M, Rapoport A, Sheftell F, Tepper D, Tepper S. Memantine in the preventive treatment of refractory migraine. Headache. 2008 Oct; 48(9):1337-42.
-
Qaseem A, Snow V, Cross JT, Forciea MA, Hopkins R, Shekelle P, Adelman A, Mehr D, Schellhase K, Campos-Outcalt D, Santaguida P, Owens DK. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2008 Mar 04; 148(5):370-8.
-
Stefanacci RG, Cafiero AC. Antidementia agents: what is important in this class. Manag Care. 2005 May; 14(5 Suppl):11-6.